Skip to content

Study · Case report or series · n = 1 · 2021

2 results

An Exceedingly Rare Case of Liraglutide-Induced Liver Injury.

Parvataneni S, Ramachandran R, Then E, Grantham T, Gaduputi V

Case reports in gastrointestinal medicine23 Aug 2021Cited by 4 (Europe PMC)

PMID34471551 (opens in a new tab)PMCIDPMC8405313 (opens in a new tab)DOI10.1155/2021/6306149 (opens in a new tab)PepBankPUB-34471551
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A case report describes liver injury attributed to liraglutide in a person treated for type 2 diabetes.

    In plain wordsIn one reported patient, liraglutide was linked to liver injury.

    Peptide
    Liraglutide
    Outcome
    IncreaseLiraglutide-induced liver injury
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.
  2. 02HumanCase report or seriesSafety outcome

    In the reported case, liver injury resolved completely after liraglutide was stopped.

    In plain wordsIn one reported patient, the liver injury went away completely after liraglutide was stopped.

    Peptide
    Liraglutide
    Outcome
    DecreaseResolution of liver injury after stopping liraglutide
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.